Watch OKUR. Know when insiders buy.
One email the day a filing lands. Free.
OKUR
OnKure Therapeutics, Inc.
2.93
−0.01 −0.34%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
3
FLAG · shorts 3
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $118.7MP/E —DIV YIELD —FCF YIELD -40.34%REV TTM —NET INCOME −$58.7MNET CASH —52W 2.32 – 5.27SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$16.9M | −$15.3M | — | -0.31 | −$10.4M | $3K | −$10.4M | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$15.6M | −$15.2M | — | -1.11 | −$12.9M | $5K | −$12.9M | Aug 4 |
| Q4 2025 · Dec 31 | — | — | — | −$14.1M | −$13.5M | — | -0.99 | −$11.5M | $9K | −$11.5M | Aug 4 |
| Q3 2025 · Sep 30 | — | — | — | −$15.5M | −$14.7M | — | -1.09 | −$13M | $6K | −$13M | Aug 4 |
| Q2 2025 · Jun 30 | — | — | — | −$16.3M | −$15.4M | — | -1.14 | −$13.3M | $13K | −$13.3M | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$17M | −$15.9M | — | -1.19 | −$14M | $18K | −$14M | Aug 4 |
| Q4 2024 · Dec 31 | — | — | — | −$18.7M | −$17.4M | −194.2% | 96.49 | −$23.4M | $15K | −$23.4M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$11.5M | −$11.6M | — | -36.55 | −$10.7M | $18K | −$10.7M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$14.3M | −$14.1M | — | -44.82 | −$6.5M | $10K | −$6.5M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$9.8M | −$9.5M | — | -30.37 | −$10.6M | $9K | −$10.6M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | $21.1M | $18.5M | — | -106.30 | $9.4M | $50K | $9.3M | Mar 10 |
| Q3 2023 · Sep 30 | — | — | — | −$20.9M | −$19.2M | — | -5.68 | −$18.8M | $19K | −$18.8M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$63M | −$59.5M | — | -4.40 | −$51.8M | $46K | −$51.9M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$54.4M | −$52.7M | — | -15.28 | −$51.1M | $52K | −$51.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$36.9M | −$35.3M | — | -124.41 | −$34.5M | $246K | −$34.8M | $4.4M | — |
| FY2022 · to Dec 31 | — | — | −$53.8M | −$52M | — | -2.12 | −$47.4M | $346K | −$47.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$39.8M | −$39.8M | — | -2.19 | −$38M | $198K | −$38.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$19.6M | −$19.5M | — | -9.60 | −$18.5M | $24K | −$18.6M | — | — |
Every number comes from OnKure Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.